Clene (CLNN) Share-based Compensation (2019 - 2026)
Clene (CLNN) posted Share-based Compensation of $3.5 million for Q2 2026, up 153.4% on a QoQ basis from $1.4 million in Q4 2025, and up 49.56% year-over-year from $2.3 million in Q2 2025.
Analysis
Clene (CLNN) Share-based Compensation (2019 - 2026) Analysis & Trends
Clene has reported Share-based Compensation for 8 years, with the latest figure at $3.5 million in Q2 2026.
- On a quarterly basis, Share-based Compensation rose 49.56% year-over-year to $3.5 million in Q2 2026; TTM through Jun 2026 was $3.5 million, a 49.56% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, down 19.75% from the prior year.
- Share-based Compensation was $3.5 million for Q2 2026 at Clene, up from $1.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $22.0 million in Q1 2024, with the low at $1.4 million in Q4 2025.
- Average Share-based Compensation over 5 years is $8.2 million, with a median of $2.7 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 76.75% in 2023, then plunged 90.81% in 2024.
- Over 5 years, Share-based Compensation stood at $2.0 million in 2022, then increased by 0.89% to $2.0 million in 2023, then declined by 12.02% to $1.8 million in 2024, then fell by 24.21% to $1.4 million in 2025, then soared by 153.4% to $3.5 million in 2026.
- The last three Share-based Compensation figures came in at $3.5 million (Q2 2026), $1.4 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | -950.00 Mn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 249.00 Mn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 277.20 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 67.26 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 19.00 Mn |
| 10 | Clene | 45.69 Mn | 45.69 Mn | 54,000.00 | 3.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.46 Mn |
| Dec 31, 2025 | 1.37 Mn |
| Sep 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 2.19 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 21.99 Mn |
| Dec 31, 2023 | 2.05 Mn |
| Sep 30, 2023 | 21.52 Mn |
| Jun 30, 2023 | 21.23 Mn |
| Mar 31, 2023 | 16.21 Mn |
| Dec 31, 2022 | 2.03 Mn |
| Sep 30, 2022 | 12.17 Mn |
| Jun 30, 2022 | 12.07 Mn |
| Mar 31, 2022 | 11.94 Mn |
| Dec 31, 2021 | 2.44 Mn |
| Sep 30, 2021 | 9.06 Mn |
| Jun 30, 2021 | 9.13 Mn |